

Joint DIA/AEMPS Statistics Workshop

Statistical Methodology in Clinical R&D

Event #14107

10-11 November 2014

Hotel Tryp Apolo | Barcelona, Spain



Programme Co-Chairs:

Ferran Torres

Scientific Director, Biostatistics and Data Management Core Facility, IDIBAPS – Hospital Clinic of Barcelona. Associate Professor, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona. Statistical Consultant Spanish Agency for Medicines and Medical Devices (AEMPS), Spain

Beatriz Seoane Núñez

Expert Statistician, Clinical Statistics Department, Almirall, Spain

Programme Committee:

Norbert Benda

Head of Biostatistics and Special Pharmacokinetics, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Hans-Ulrich Burger

Senior Director of Biostatistics, F. Hoffmann-La Roche AG, Switzerland

William Malbecq

Executive Director Biostatistics, MSD Europe, Brussels, Belgium

Tim Friede

Professor of Biostatistics, Chair, Department of Medical Statistics, University Medical Centre Göttingen, Germany

Geert Verbeke

Professor of Biostatistics, Department of Public Health and Primary Care, KU Leuven, Belgium

Scientific Advisor:

Michael Branson

Global Head Full Development Biostatistics, Oncology Business Unit, Novartis Pharma AG, Switzerland

The DIA Statistics Community

is strongly involved in the development of this programme. Become a DIA Member now to be part of this global community, that involves pharmaceutical and regulatory statisticians as well as academia.

Overview

Lifecycle management is a widely accepted concept for the development and marketing of medicines. At each step of this process, pre- and post-licensing, statisticians work to develop methods that can improve efficiency and can enhance decision-making through optimal study design, analysis and inference. The discussions at this workshop will consider not only the methods themselves, but also how to best implement them in a regulatory context.

We will focus on:

- Different views on the choice of an appropriate estimand and related design options and analysis models in the context of the definition of a trial objective taking into account possible non-adherence to the assigned treatment
- Statistical aspects of components required for Market Access in the development of a biosimilar in view of recent attention to methodological issues in the assessment of biosimilarity and biological products due to differences between biosimilars and small molecule generics
- Illustrating the use of innovative methods to identify subgroups that benefit in particular from a new treatment and how to integrate this knowledge into clinical development plans through adaptive and enrichment designs to develop personalised / stratified treatment strategy

Key Topics

- Lack of adherence and the choice of the right estimand in clinical trials
- Statistical approaches in biosimilarity
- How precise can precision medicine be?
- Key topics in regulatory statistics and activities, including recent positive opinions.

Who Will Attend

Professionals with an interest in the application of, and research into, statistics in the drug development process from the pharmaceutical industry, academia, regulatory and governmental agencies as well as contract research organisations.

Continuing Education

DIA meetings and training courses are generally approved by the Commission for Professional Development (CPD) of the Swiss Association of Pharmaceutical Professionals (SwAPP) and the Swiss Society of Pharmaceutical Medicine (SGPM) and will be honoured with credits for pharmaceutical medicine. All participants are eligible for these credits and certificates are available.

Please contact magdalena.lewandowska@diaeurope.org or visit www.diahome.org for more information.



MONDAY | 10 NOVEMBER 2014

12:30 REGISTRATION AND WELCOME COFFEE

14:00 Session 1

LACK OF ADHERENCE AND THE CHOICE OF THE RIGHT ESTIMAND IN CLINICAL TRIALS

Session Co-chairs:

Norbert Benda, Head of Biostatistics and Special Pharmacokinetics, Federal Institute for Drugs and Medical Devices (BfArM), Germany**William Malbecq**, Executive Director Biostatistics, MSD Europe, Brussels, Belgium

Recently, an ICH concept paper on choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials was drafted. In settings where pronounced lack of adherence to the study protocol is expected, the difference between the ideal treatment effect, if the medication is taken as directed, and the treatment effect if the medication is taken as observed is crucial in the assessment of the drug's benefit. The handling of missing data and the use data observed after treatment discontinuation or change is strongly related to the targeted estimand. An estimand is what is being estimated and precisely defines a treatment effect regarding population, outcome measure, and the parameter defined by the underlying probabilistic model either under the assumption of perfect treatment adherence or incorporating the actual adherence. The session will discuss the use and definition of different estimands and the consequences with respect to study design and analysis in the context of the drug approval process.

Estimands and Their Role in Clinical Trials: Defining suitable primary scientific questions of interest

Mouna Akacha, Statistical Methodologist, Novartis Pharma AG, Switzerland

The Estimand: An ugly necessity, a pie in the sky or a useful tool?

Michael O'Kelly, Senior Director, Centre for Statistics in Drug Development, Innovation, Quintiles Ireland Ltd, Ireland

Statistical Models for De Facto Estimands

James Roger, London School of Hygiene & Tropical Medicine, UK

15:30 COFFEE BREAK

16:00 Session 1 continued

LACK OF ADHERENCE AND THE CHOICE OF THE RIGHT ESTIMAND IN CLINICAL TRIALS**Applicability and Appropriateness of De-facto and De-jure Estimands in Drug Approval**

Ann-Kristin Leuchs, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Estimands and the Handling of Missing Data: Regulatory Evolution

David Brown, Expert Statistical Assessor, MHRA, UK

Panel Discussion with Questions and Answers

Concha Prieto, Centralized Procedure Unit CHMP Member Spanish Agency for Drugs and Medical Devices, Spain

Erik Cobo, Profesor Titular de Universidad Politecnica Catalunya, Spain

Rosa Lamarca, Head of Biometry Laboratorios, Almirall, Spain

17:30 NETWORKING RECEPTION

18:30 END OF DAY ONE

TUESDAY | 11 NOVEMBER 2014

09:00 Session 2

STATISTICAL APPROACHES IN BIOSIMILARITY

Session Co-Chairs:

Beatriz Seoane Núñez, Expert Statistician, Clinical Statistics Department, Almirall, Spain**Ferran Torres**, Scientific Director, Biostatistics and Data Management Core Facility, IDIBAPS - Hospital Clinic of Barcelona. Associate Professor, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona. Statistical Consultant Spanish Agency for Medicines and Medical Devices (AEMPS), Spain

Biosimilar medicines is a growing field. The number of regulatory applications has increased in recent years. This session will highlight the features of the study design options for biosimilar efficacy trials. The choice of margins, their reliability and the different statistical and regulatory considerations associated with them will be some of the topics that will be discussed in this session from both a regulatory and industry point of view.

Statistical Challenges in Biosimilarity - A regulator's view

Peter Volkers, Paul-Ehrlich-Institut, Germany

Statistical Challenges and Current Experience in Biosimilarity Trial Designs

Yulan Li, Director Biostatistics, Biosimilars Oncology Biometrics & Data Management, Novartis Pharmaceuticals Corporation, USA

Panel Discussion with Questions and Answers

Gonzalo Calvo, ex-CHMP member, Chairman of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Consultant in Clinical Pharmacology - Hospital Clinic of Barcelona.

Antonio Gomez-Outes, Clinical Assessor, Cardiovascular, Respiratory and Gastrointestinal Drugs, Spanish Agency for Medicines and Medical Devices (AEMPS), Spain

10:30 COFFEE BREAK

11:00 Session 3

HOW PRECISE CAN PRECISION MEDICINE BE?

Session Co-chairs:

Tim Friede, Professor of Biostatistics, Chair, Department of Medical Statistics, University Medical Centre Göttingen, Germany**Hans-Ulrich Burger**, Senior Director of Biostatistics, F. Hoffmann-La Roche AG, Switzerland

Precision medicine is becoming more and more important in drug development. Among the many possible topics we picked two: biomarker identification and seamless enrichment designs. There will be a short introduction to the topic, an overview and different methods, followed by two examples from industry and a regulatory evaluation. Finally the two sessions will be rounded up by a panel discussion.

Adaptive Enrichment Designs for Stratified Medicine

Tim Friede, Professor of Biostatistics, Chair, Department of Medical Statistics, University Medical Centre Göttingen, Germany

How Good is Your Biomarker? Comparison of development plans for confirmatory biomarker enrichment

Kaspar Rufibach, Biostatistician, Oncology Biostatistics, F. Hoffmann-La Roche AG, Switzerland

Bayesian Approaches to Enrichment Designs

Heinz Schmidli, Senior Expert Statistical Methodologist Novartis Pharma AG, Switzerland

12:30 LUNCH

14:00 Session 3 continued

HOW PRECISE CAN PRECISION MEDICINE BE?**Regulatory Views of Precision Medicine**

Norbert Benda, Head of Biostatistics and Special Pharmacokinetics, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Key Issues in Enrichment Designs from a Development Point of View: An introduction to the panel discussion

Hans-Ulrich Burger, Senior Director of Biostatistics, F. Hoffmann-La Roche AG, Switzerland

Panel Discussion with Questions and Answers

Fernando de Andrés, Spanish Medicines Agency (AEMPS), Professor of Pharmacology at Madrid's Universidad Complutense, Spain.

15:30 COFFEE BREAK

16:00 Session 4

KEY TOPICS IN REGULATORY STATISTICS

Session Co-chairs:

Hans-Ulrich Burger, Senior Director of Biostatistics, F. Hoffmann-La Roche AG, Switzerland

Norbert Benda, Head of Biostatistics and Special Pharmacokinetics, Federal Institute for Drugs and Medical Devices (BfArM), Germany

This session will pick up two relevant topics which are important for regulatory bodies as well as for industry. For each of the topics we will have one presentation from a more regulatory view and a panel discussion. The first topic will deal with issues in developing new therapies in small populations, rare diseases and paediatric indications. The second issue will discuss issues around censoring for time to event analyses and what the right primary analysis should be.

Overview on Issues in Developing New Therapies in Small Populations, Rare Diseases and Paediatric Indications

Kit Roes, Director Quality and Patient Safety, UMC Utrecht, the Netherlands

Overview on Censoring Rules for Time to Event Analysis. What Should be the Primary Endpoint?

Hans-Ulrich Burger, Senior Director of Biostatistics, F. Hoffmann-La Roche AG, Switzerland

20 Years of ICH E4 -Dose-Response / Dose-Finding Quo Vadis?

Andrew Grieve, Senior Vice President Clinical Trial Methodology, Aptiv Solutions, Germany

Statistical Analysis in Alzheimer's Disease

David Brown, Expert Statistical Assessor, MHRA, UK

Panel Discussion with Questions and Answers

17:30 END OF CONFERENCE

HOTEL INFORMATION

DIA has blocked a limited number of rooms at the following hotel:

TRYP Barcelona Apolo Hotel

Avinguda del Paral·lel, 57-59,

08004, Barcelona, Spain

Tel: (34) 93 343 30 00

Fax: (34) 93 443 0059

E-mail: tryp.apolo@melia.com

at the rate of:

EUR 85.00 single use

incl. of breakfast, excl. of VAT and city tax

To make your reservation, please click here: <http://meetings.melia.com/en/DIAEUROPE.html>

Important: The room rate is available until 04 October 2014 or until the group block is sold-out, whichever comes first.

In case of no-shows the hotel is authorised to charge the full amount corresponding to the duration of your stay.

About AEMPS

The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) is the State Agency affiliated with the Spanish Ministry of Health, Social Services and Equality, which guarantees quality, safety, efficacy and accurate information on medicines and medical devices marketed in Spain.

AEMPS started its activity in 1999, since then and up to today, AEMPS has experienced a great increase in its activities, developing new competences (both in Spain and across Europe) and establishing itself as a key reference body for the public with regard to medicines and medical devices.

The most important legislation governing the activities of the AEMPS is the Law 29/2006 of 26th of July (updated by Law 10/2013 of 24th July), about guarantees and rational use of medicines and medical devices, as well as various other royal decrees regulating each area of intervention.

AEMPS protects public health by means of authorizations and controls which it carries out on medicines for human use, veterinary medicines, medical devices, cosmetics and hygiene products, clinical research or laboratories and manufacturer companies.

As a public service, the mission of the AEMPS is to give guarantees to the general public on the quality, safety, efficacy and accurate information on medicines and medical devices, in the widest remit, from research to end use, to protect and promote health in both human beings and animals.

Its vision is to strengthen the sanitary authority of reference for citizens and healthcare professionals with regard to guarantees of quality, safety, efficacy, information and accessibility of medicines and medical devices.

About DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation headquartered in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China.

For more information, visit www.diahome.org or call DIA Europe +41 61 225 51 51.

DIA Mission

DIA fosters innovation to improve health and well-being worldwide by:

- Providing invaluable forums to exchange vital information and discuss current issues related to health products, technologies, and services;
- Delivering customized learning experiences;
- Building, maintaining, and facilitating trusted relationships with and among individuals and organisations that drive and share DIA values and mandates; and
- Offering a multidisciplinary neutral environment, respected globally for integrity and relevancy.

DIA Vision

DIA is the global forum for knowledge exchange in the pharmaceutical sector that fosters innovation to raise the level of health and well-being worldwide



REGISTRATION FORM

Joint DIA/AEMPS Statistics Workshop
10-11 November 2014 | Barcelona, Spain



ID #14107

Early-bird rates available for members: Register by 29 September 2014

Join DIA now to qualify for the Early-bird member fee! The Early-bird registration form and accompanying payment must be received by the date above.
Early-bird fee applies to industry members only. (www.diahome.org/membership)

€ 1'220.00

FEES (after 30 September 2014)

	Member*	Non-Member*
Industry	€ 1'420.00 <input type="checkbox"/>	€ 1'550.00 <input type="checkbox"/>
Academia/Charitable/Government/Non-profit (Full-time)	€ 710.00 <input type="checkbox"/>	€ 840.00 <input type="checkbox"/>

Join DIA now to qualify for the member rate

€ 130.00

* All fees will be subject to the local Spanish 10% VAT

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee.

Group discount/SME rates available. Special rates for students and patient representatives on offer, subject to availability – please contact DIA Europe for more information.

Registration fee includes: refreshments, lunches and meeting material.

Payment is due 30 days after registration and must be paid in full by commencement of the event.

ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee's business card here.

Prof Dr Ms Mr

Last Name

First Name

Company

Job Title

Address

Postal Code City

Country

Telephone

Fax

Email*

*(Required for confirmation)

DIA reserves the right to include your name and affiliation on the attendee list.

PAYMENT METHODS

Credit cards: 5% charge will be added when paying by credit card. Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

Please charge my VISA MC AMEX

Card N°

Exp. Date /

Cardholder's Name

Bank transfers: When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Event ID #14107 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA Europe.**

By signing below, I confirm that I agree with DIA Europe's Terms and Conditions of booking. These are available from the office or on <http://www.diahome.org/EUTerms>

Date

Signature

Cancellation Policy

All cancellations must be made in writing and be received at the DIA Europe office five working days prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00
- Tutorial cancellation € 50.00

If you do not cancel five working days prior to the event start date and do not attend, you will be responsible for the full registration fee. DIA Europe reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA Europe is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA Europe office of any such substitutions as soon as possible.

Photography Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA Europe in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.